| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4174400 | Pediatric Clinics of North America | 2008 | 26 Pages |
Abstract
Allogeneic stem cell transplantation (SCT) is the only curative approach for many patients with advanced or high-risk leukemia. Advances in supportive care and management of graft-versus-host disease have resulted in improvements in outcomes of related and unrelated donor SCT, creating controversies as to which strategy might be the optimal therapy for individual patients. This article discusses the indications and donor selection strategies for SCT in patients with malignant hematologic disease.
Related Topics
Health Sciences
Medicine and Dentistry
Perinatology, Pediatrics and Child Health
Authors
Rupert Handgretinger, Joanne Kurtzberg, R. Maarten Egeler,